PMID- 20059881
OWN - NLM
STAT- MEDLINE
DCOM- 20100309
LR  - 20131121
IS  - 1214-6994 (Print)
IS  - 1214-6994 (Linking)
VI  - 110
IP  - 4
DP  - 2009
TI  - Microvascular Reactivity and Endothelial Function in Type 2 Diabetic Patients 
      with Hyperlipidemia Treated with Simvastatin: 3-year Follow-up.
PG  - 290-300
AB  - Aim of this study was to evaluate microvascular reactivity (MVR) by laser Doppler 
      flowmetry in Type 2 diabetes mellitus (T2DM) with hyperlipidemia during three 
      years of simvastatin treatment. Additionally, markers of endothelium and 
      fibrinolysis were evaluated. Twenty patients with T2DM and hyperlipidemia were 
      treated with 20 mg of simvastatin daily for 3 months, treatment was then 
      interrupted for 3 months (wash-out) and again started and maintained continually 
      up to total of 36 months of follow-up. Maximal perfusion (max), velocity of 
      perfusion increase (max/t) and percent increase of perfusion compared to baseline 
      (%) was measured during post-occlusive reactive hyperemia (PORH) and thermal 
      hyperemia (TH). VCAM-1, ICAM-1, E-selectin and P-selectin were used as markers of 
      endothelium, tissue plasminogen activator (tPA) and its inhibitor (PAI-1) as 
      markers of fibrinolysis. Baseline MVR in diabetic patients was comparable to 
      controls. MVR decreased at months 3, 12, and 36 compared to baseline (PORHmax 
      26+/-12, 35+/-17, 26+/-11 vs. 56+/-30 PU, p<0.05, THmax 67+/-19, 81+/-37, 58+/-24 
      vs. 134+/-70 PU, p<0.01, PORHmax/t 2.0+/-1.4, 2.8+/-1.7, 1.9+/-1.3 vs. 7.7+/-7.4 
      PU/s, p<0.05, THmax/t 1.1+/-0.6, 1.0+/-0.4, 0.7+/-0.4 vs. 1.5+/-0.7 PU/s, p<0.05.
FAU - Prazny, M
AU  - Prazny M
AD  - Charles University in Prague, First Faculty of Medicine, 3rd Department of 
      Internal Medicine, Prague, Czech Republic. mpra@LF1.cuni.cz
FAU - Kasalova, Z
AU  - Kasalova Z
FAU - Mazoch, J
AU  - Mazoch J
FAU - Kvasnicka, J
AU  - Kvasnicka J
FAU - Skrha, J
AU  - Skrha J
LA  - eng
PT  - Journal Article
PL  - Czech Republic
TA  - Prague Med Rep
JT  - Prague medical report
JID - 101227436
RN  - 0 (Cell Adhesion Molecules)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Lipids)
RN  - AGG2FN16EV (Simvastatin)
SB  - IM
MH  - Cell Adhesion Molecules/blood
MH  - Diabetes Mellitus, Type 2/blood/complications/*physiopathology
MH  - Endothelium, Vascular/*physiopathology
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Hyperlipidemias/blood/complications/*drug therapy
MH  - Hypolipidemic Agents/*therapeutic use
MH  - Laser-Doppler Flowmetry
MH  - Lipids/blood
MH  - Male
MH  - Microcirculation/*physiology
MH  - Middle Aged
MH  - Simvastatin/*therapeutic use
MH  - Skin/blood supply
MH  - Vasodilation/physiology
EDAT- 2010/01/12 06:00
MHDA- 2010/03/10 06:00
CRDT- 2010/01/12 06:00
PHST- 2010/01/12 06:00 [entrez]
PHST- 2010/01/12 06:00 [pubmed]
PHST- 2010/03/10 06:00 [medline]
AID - PMR2009A0032 [pii]
PST - ppublish
SO  - Prague Med Rep. 2009;110(4):290-300.